These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

313 related items for PubMed ID: 26140377

  • 1. Stepchild or Prodigy? Neuroprotection in Multiple Sclerosis (MS) Research.
    Rottlaender A, Kuerten S.
    Int J Mol Sci; 2015 Jul 01; 16(7):14850-65. PubMed ID: 26140377
    [Abstract] [Full Text] [Related]

  • 2. Neuronal injury in chronic CNS inflammation.
    Zindler E, Zipp F.
    Best Pract Res Clin Anaesthesiol; 2010 Dec 01; 24(4):551-62. PubMed ID: 21619866
    [Abstract] [Full Text] [Related]

  • 3. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade.
    Van der Walt A, Butzkueven H, Kolbe S, Marriott M, Alexandrou E, Gresle M, Egan G, Kilpatrick T.
    Pharmacol Ther; 2010 Apr 01; 126(1):82-93. PubMed ID: 20122960
    [Abstract] [Full Text] [Related]

  • 4. Multiple sclerosis - remyelination failure as a cause of disease progression.
    Hagemeier K, Brück W, Kuhlmann T.
    Histol Histopathol; 2012 Mar 01; 27(3):277-87. PubMed ID: 22237705
    [Abstract] [Full Text] [Related]

  • 5. [Neuroprotection in the treatment of multiple sclerosis].
    Zipp F, Gold R.
    Nervenarzt; 2011 Aug 01; 82(8):973-7. PubMed ID: 21761185
    [Abstract] [Full Text] [Related]

  • 6. Neuroprotection in multiple sclerosis: a therapeutic approach.
    Maghzi AH, Minagar A, Waubant E.
    CNS Drugs; 2013 Oct 01; 27(10):799-815. PubMed ID: 23955320
    [Abstract] [Full Text] [Related]

  • 7. Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.
    Ziemssen T.
    J Neurol; 2005 Nov 01; 252 Suppl 5():v38-45. PubMed ID: 16254701
    [Abstract] [Full Text] [Related]

  • 8. [Axonal damage and its significance for the concept of neurodegeneration in multiple sclerosis].
    Recks MS, Bader J, Kaiser CC, Schroeter M, Fink GR, Addicks K, Kuerten S.
    Fortschr Neurol Psychiatr; 2011 Mar 01; 79(3):161-70. PubMed ID: 21394707
    [Abstract] [Full Text] [Related]

  • 9. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis.
    Loeb JA.
    Neurology; 2007 May 29; 68(22 Suppl 3):S38-42; discussion S43-54. PubMed ID: 17548567
    [Abstract] [Full Text] [Related]

  • 10. Axonal degeneration in multiple sclerosis: defining therapeutic targets by identifying the causes of pathology.
    Lee JY, Biemond M, Petratos S.
    Neurodegener Dis Manag; 2015 Dec 29; 5(6):527-48. PubMed ID: 26619755
    [Abstract] [Full Text] [Related]

  • 11. Advancing therapeutic options in multiple sclerosis with neuroprotective properties.
    Stroet A, Linker RA, Gold R.
    J Neural Transm (Vienna); 2013 Sep 29; 120 Suppl 1():S49-53. PubMed ID: 23720188
    [Abstract] [Full Text] [Related]

  • 12. Neurodegeneration and neuroprotective agents in multiple sclerosis.
    Fong JS, Rae-Grant A, Huang D.
    Recent Pat CNS Drug Discov; 2008 Nov 29; 3(3):153-65. PubMed ID: 18991805
    [Abstract] [Full Text] [Related]

  • 13. Remyelinating strategies in multiple sclerosis.
    Luessi F, Kuhlmann T, Zipp F.
    Expert Rev Neurother; 2014 Nov 29; 14(11):1315-34. PubMed ID: 25331418
    [Abstract] [Full Text] [Related]

  • 14. Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection.
    Neuhaus O, Archelos JJ, Hartung HP.
    Trends Pharmacol Sci; 2003 Mar 29; 24(3):131-8. PubMed ID: 12628358
    [Abstract] [Full Text] [Related]

  • 15. Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment.
    De Santi L, Polimeni G, Cuzzocrea S, Esposito E, Sessa E, Annunziata P, Bramanti P.
    Curr Med Chem; 2011 Mar 29; 18(12):1775-84. PubMed ID: 21466473
    [Abstract] [Full Text] [Related]

  • 16. The role of neurotrophic factors in the pathology and treatment of multiple sclerosis.
    Mirowska-Guzel D.
    Immunopharmacol Immunotoxicol; 2009 Mar 29; 31(1):32-8. PubMed ID: 18792835
    [Abstract] [Full Text] [Related]

  • 17. Axonal loss in multiple sclerosis: causes and mechanisms.
    Criste G, Trapp B, Dutta R.
    Handb Clin Neurol; 2014 Mar 29; 122():101-13. PubMed ID: 24507515
    [Abstract] [Full Text] [Related]

  • 18. Axonal damage in multiple sclerosis: a complex issue in a complex disease.
    Grigoriadis N, Ben-Hur T, Karussis D, Milonas I.
    Clin Neurol Neurosurg; 2004 Jun 29; 106(3):211-7. PubMed ID: 15177770
    [Abstract] [Full Text] [Related]

  • 19. Remyelinating and neuroprotective treatments in multiple sclerosis.
    Stangel M.
    Expert Opin Investig Drugs; 2004 Apr 29; 13(4):331-47. PubMed ID: 15102584
    [Abstract] [Full Text] [Related]

  • 20. Prospects for neuroprotection in multiple sclerosis.
    Yong VW.
    Front Biosci; 2004 Jan 01; 9():864-72. PubMed ID: 14766415
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.